We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

SENS:NASDAQSenseonics Holdings, Inc. Analysis

Data as of 2026-04-30 - not real-time

$6.43

Latest Price

8/10Risk

Risk Level: High

Executive Summary

Senseonics is trading well below its short‑term moving averages, with the 20‑day and 50‑day SMAs positioned above the current price while the 200‑day SMA remains higher, underscoring a bearish technical backdrop. RSI in the low‑40s points to modest downside momentum, yet the MACD has just turned bullish, though the histogram is still thin, suggesting limited near‑term upside. The stock’s beta is markedly above one and 30‑day volatility exceeds 50%, amplifying price swings, and the historical max drawdown has been severe. On the fundamentals side, revenue is accelerating at a robust >70% year‑over‑year rate, but margins are deeply negative and cash flow remains negative despite a cash pile that exceeds debt. Valuation metrics such as price‑to‑book and price‑to‑sales are high relative to book value, and analysts collectively rate the stock as a buy with a target price nearly three times the current level. The recent European launch of the year‑long Eversense 365 CGM provides a tangible catalyst that could help narrow the gap between current pricing and analyst expectations.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 5/10

Key Factors

  • price remains below short‑term moving averages
  • RSI indicates modest downside pressure
  • European product launch could act as a near‑term catalyst

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • strong revenue growth trajectory
  • new CGM system expanding addressable market
  • analyst target price implies significant upside

Long Term

> 3 years
Positive
Model confidence: 8/10

Key Factors

  • long‑term demand for implantable continuous glucose monitoring
  • potential for recurring revenue from sensor replacements
  • high upside potential despite current losses

Key Metrics & Analysis

Financial Health

Revenue Growth71.80%
Profit Margin-196.03%
P/E Ratio-2.4
ROE-168.27%
ROA-37.68%
Debt/Equity67.77
P/B Ratio4.3
Op. Cash Flow$-59129000
Free Cash Flow$-46501000
Industry P/E25.2

Technical Analysis

TrendBearish
RSI41.6
Support$6.36
Resistance$7.45
MA 20$6.82
MA 50$6.87
MA 200$7.70
MACDBullish
VolumeStable
Fear & Greed Index88.3

Valuation

Target Price$18.92
Upside/Downside194.42%
GradeOvervalued
TypeGrowth

Risk Assessment

Beta2.07
Volatility51.33%
Sector RiskMedium
Reg. RiskHigh
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.